Core Viewpoint - The company,药捷安康, announced a share placement agreement to raise funds for clinical trials and product development, with a significant discount on the share price compared to the market rate [1] Group 1: Share Placement Details - The company entered into a placement agreement with a placement agent to sell 2.1 million shares at a price of HKD 92.85 per share [1] - The placement price represents a discount of approximately 17.98% from the closing price reported on the Hong Kong Stock Exchange on the same day [1] Group 2: Use of Proceeds - The net proceeds from the placement are expected to be approximately HKD 190.14 million [1] - About 60% of the funds will be allocated to clinical trials for the company's core product, Tinengotinib, specifically for its use in treating cholangiocarcinoma (CCA) [1] - Approximately 30% of the proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be allocated for working capital and general corporate purposes [1]
药捷安康：拟折让17.98%配售210万股H股，净筹约1.9亿港元
Xin Lang Cai Jing·2026-01-13 23:59